Related Experiment Video
Updated: Jun 3, 2026
06:07
Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
Published on: June 23, 2023
GPA protects the nigrostriatal dopamine system by enhancing mitochondrial function
Tamas L Horvath1, Derek M Erion, John D Elsworth
1Section of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA.
Neurobiology of Disease
|March 17, 2011
Summary
Guanidinopropionic acid (GPA) protects against Parkinson's disease in mice by preserving dopamine neurons and enhancing mitochondrial function. This suggests GPA may be a potential therapeutic agent for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Mitochondrial Biology
- Pharmacology
Background:
- Mitochondrial dysfunction is implicated in Parkinson's disease pathogenesis.
- Guanidinopropionic acid (GPA) enhances mitochondrial function and AMPK activity in muscle.
Purpose of the Study:
- To investigate the neuroprotective effects of GPA on the nigrostriatal dopamine system in a mouse model of Parkinson's disease (MPTP-treated mice).
- To determine if GPA-mediated neuroprotection involves AMPK activation and improved mitochondrial function.
Main Methods:
- Mice were fed a 1% GPA diet or normal chow, followed by MPTP or saline treatment.
- Neuroprotection was assessed using HPLC, immunohistochemistry, stereology, electron microscopy, and mitochondrial respiration assays.
- AMPK activity, mitochondrial number, and dopamine levels were quantified.
Main Results:
- GPA treatment prevented the loss of tyrosine hydroxylase (TH) neurons in the substantia nigra pars compacta (SNpc) following MPTP intoxication.
- GPA significantly attenuated MPTP-induced decreases in striatal dopamine levels.
- GPA increased AMPK activity, mitochondrial respiration, and mitochondrial number in nigrostriatal TH neurons, while preventing MPTP-induced mitochondrial damage.
Conclusions:
- Guanidinopropionic acid (GPA) exhibits neuroprotective properties in a mouse model of Parkinson's disease.
- The neuroprotective effects of GPA are partially mediated by AMPK-dependent enhancement of mitochondrial function and biogenesis.
- GPA holds potential for slowing disease progression in neurodegenerative conditions characterized by mitochondrial dysfunction.
Related Concept Videos
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
00:49The Blood-brain Barrier
Overview